(). |
|
|
EVMS COVID-19 |
|
Paul Marik, MD , , 2020
EVMS COVID: https://www.evms.edu/covid-19/medical_information_resources/ SHort URL: evms.edu/covidcare
COVID-19
( COVID-19), «» / COVID-19, ; , 60 , . , ; , . ?
• 500 250-500
• 75-100 / (, ). . 1-2 30-50 / .
• ( ): 0,3 1-2
• D3 1000-4000 / ( ). , , 25-OH D , 40 ° , .
:
• 500 250-500 ( )
• 75-100 /
• 6-12 ( )
• D3 1000-4000 /
• 40-60 ( ; CrCl <30 / )
• ( ): 500 5 400 , 200 4
• . • N / C 2 / , (. 4 / ; t / f ).
• . «Spinhaler» MDI , .
•
• / .
(SOB; , N / C ≥ 4 , : ):
1. 500 5 400 , 200 4 .
2. ( ) 3 / 6 7 . (. ): . POC ().
3. . , ( ) , 1 / / 12 ( Cr Cl <30 / ). CrCl <15 / . 3 18 | EVMS Critid Care COVID-19 04-06-2020 | evms.edu/covidcare : rTPA: 25 tPA 2 25 tPA, 22 , , 0,9 / , . 40-60 / .
4. : 50 q 6 7 60 IV 7 .
5. 200 q 12 ( IV).
6. 500 1, 250 4 ( , IL-6; , Rx ).
7. 6-12 ( ).
8. 75-100 .
9. : 2 IV. Mg 2,0 2,4 / . ( Qtc).
10. . ( ). , -, , . , ( ).
11. EUVOLEMIA ( ). - « » (6-8 ) . 500 , . , .
12. . II Giapreza ™ , COVID-19 ( ACE-2).
13. : 40-80 / . , . , . , , . , PAI-1.
14. : ( ) ( IL-6).
15. : a. COVID-19 ( ) (60 7 ). , . b. . c. / (6-8- ) : 50 IV q 6 7 . d. HLH / , , CRP, IL-6 . . ( 200-500 , .12).
16. / HLH . CVVH,
18.
• : PCT, CRP, IL-6, BNP, , , , D-, Mg, CRP . () , .
• , , Accu-Chek ™ POC . .
• QTc / Mg ++ (torsades )
• , CXR .
• ECHO;
|
|
|
:
«»; ; 13; 2010; . 63-67.
.. , .. 7, “ ",
() () (). 7 36 , 20 . . SPSS 13.0 . < 0,05. . . , , , , , , γ-, , . , () , , .
: , , , ,
Effectiveness of use of taurine (Dibicor) in the treatment of non-alcoholic fatty liver disease (NAFLD) in the stage of steatohepatitis (NASH) was estimated. In the MCH 7, Novosibirsk, 36 patients of both sexes with NASH with minimal biochemical activity received comprehensive treatment, 20 of them received the drug Dibicor. All patients underwent anthropometric and laboratory physical examination before the study and after 1 month of treatment. Statistical analysis of the results was performed using SPSS 13,0 software package with the definition of levels of statistical significance. Value of p < 0,05 was considered statistically significant. Improvement of general condition was observed in patients of both groups. Side effects against the background of the treatment with drug Dibicor were not revealed. In the group treated with Dibicor, improved lipid profile, decreased levels of free bilirubin, fibrinogen, alkaline phosphatase, Y- glutamyltranspeptidase, glycemia, decreased body mass index and diastolic blood pressure were observed. It is concluded that Dibicor (taurine) is a physiological and safety drug with hepatoprotective and hypolipidemic effects in patients with NASH associated with obesity, and may be included in the treatment regimen of NASH.
Key words: non-alcoholic fatty liver disease, steatohepatitis, lipid metabolism, hepatoprotection, taurine
, , — , , . . , . , . , , .
, . . . . (). , . [7, 13]. () -, .
: , , . . . , .
XX . , . , , , , , , , , , , .
125 /. . . , , .
, . () , , , , , , , mRNA , β [1] 1; [8]. (- C57BL/6) . , [9]. - . - . , [12]. , [11]. , (), (). , [14].
. Hu Y.H. . , 2 3 3 , , , [10]. () . - , , , () 500 3 , , . , - . , (). , , [4].
, , . , . , 1 2, [1-3, 5, 6].
() .
- , , ( - 30, - 20 /). , .
, .
1. , .
2. . “ ” “” .
3. , , .
4. , .
: , , , .
, 7 , 36 ( - 1,5 2, 5 ) 18 65 . : , , , , ; .
“ ” () . (, ). . . , , , , , , (n = 20) 0,5 2 20 .
, , () () , , (), Y- (), , (), () (), (); : = (-)/. , () (), , (/ ). SPSS 13.0 . < 0,05. ( — ).
: , , . .
(. 1 2) () - , (. 2) : , ( < 0,05); , , , , ( < 0,05). (. 3, < 0,01) 1 (. 3) (. 4).
1
1 ( )
(M ± m) | (M ± m) | |||
, / | 2,81 ± 0,69 | 2,25 ± 0,19 | 0-3 | |
, / | 16,19 ± 2,48 | 16,37 ± 0,73 | 0-15 | |
, / | 5,030 ± 0,216 | 5,025 ± 0,190 | 4,0-6,1 | |
, / | 3,26 ± 0,13 | 3,17 ± 0,10 | 2-4 | |
, / | 0,930 ± 0,027 | 0,61 ± 0,05 | < 0,0004 | 0,1-0,68 |
, / | 0,690 ± 0,032 | 0,4500 ± 0,0039 | < 0,0005 | 0,1-0,45 |
, / | 253,62 ± 17,98 | 246,25 ± 11,93 | 70-270 | |
, / | 41,13 ± 5,04 | 29,31 ± 1,74 | < 0,01 | . 40, . 60 |
, / | 5,63 ± 0,24 | 5,69 ± 0,21 | 3,4-5,3 | |
-, | 0,63 ± 0,02 | 0,580 ± 0,014 | < 0,03 | 0,35-0,55 |
, / | 1,08 ± 0,029 | 1,05 ± 0,02 | 1,2 | |
4,13 ± 0,33 | 4,27 ± 0,14 | 3,0 | ||
, / | 1,520 ± 0,036 | 1,48 ± 0,52 | < 0,04 | 0-2,3 |
2.
2 ( )
(M ± m) | (M ± m) | , | ||
, / | 2,91 ± 0,23 | 2,42 ± 0,17 | 0-3 | |
, / | 11,88 ± 0,85 | 14,35 ± 0,53 | < 0,02 | 0-15 |
, / | 5,57 ± 0,42 | 5,13± 0,30 | < 0,03 | 4,0-6,1 |
, / | 3,72 ± 0,11 | 2,98 ± 0,08 | < 0,0007 | 2-4 |
, / | 1,08 ± 0,05 | 0,516 ± 0,035 | < 0,0001 | 0,1-0,68 |
, / | 0,96 ± 0,05 | 0,40 ± 0,0273 | < 0,0001 | 0,1-0,45 |
, / | 278 ± 16,79 | 229,4 ± 4,32 | < 0,011 | 70-270 |
, / | 42,4 ± 7,26 | 25,1 ± 2,28 | < 0,02 | . 40, . 60 |
, / | 5,44 ± 0,17 | 5,12 ± 0,12 | < 0,04 | 3,4-5,3 |
-, | 0,56 ± 0,022 | 0,55 ± 0,022 | 0,35-0,55 | |
, / | 1,086 ± 0,024 | 1,17 ± 0,031 | 1,2 | |
4,05 ± 0,16 | 3,28 ± 0,24 | < 0,002 | 3,0 | |
, / | 1,67 ± 0,04 | 1,56 ± 0,05 | < 0,04 | 0-2,3 |
3
, /
(M ± m) | (M ± m) | , | |||
1 | () | 92,47 ± 3,6 | 92,16 ± 3,6 | ||
34,32 ± 1,08 | 34,24 ± 1,09 | 18,5-25 | |||
/ | 0,88 ± 0,024 | 0,89 ± 0,024 | |||
2 ( ) | () | 102,62 ± 4,79 | 100,15 ± 43,64 | < 0,0001 | |
38,2 ± 1,93 | 37,37 ± 1,87 | < 0,0002 | 18,5-25 | ||
/ | 0,91 ± 0,02 | 0,91 ± 0,02 |
4
(M ± m) | (M ± m) | , | |||
1 | ( . .) | 140,3 ± 4,04 | 126,25 ± 8,8 | < 0,010 | 120-140 |
( . .) | 87,81 ± 1,64 | 79,69 ± 5,5 | < 0,014 | 70-90 | |
2 ( ) | ( . .) | 137 ± 2,6 | 122 ± 6,62 | < 0,013 | 120-140 |
( . .) | 85,25 ± 1,76 | 77,25 ± 1,86 | < | 70-90 |
-. , .
, () , , . , , .
|
- inna_sharfik |
|
.
R- .
- , , – .
, — , , , , .. , .
, – , Q10 — , !) , ( ).
=====
, :
, α- .
- , , (7)
- ,
- .
(13)
- .
, :
( ) , (14);
, .. .
- .
, .. - TH-1 TH-2, , (15, 16, 17)
=====
===== 2 1
- . – , , - , . .
.
=====
- , ,
(18)
- (19)
- (20)
=====
- (BMD) (23)
===== -
- , (32)
- , (34)
- - (), («» ) (33)
- , , , .
=====
, , - , .
=====
=====
- , . . 4 , .
, , , . .
=====
« , Proceedings of the National Academy of Sciences, , - (ALA) -L- (ALC) . , , , , , . , , .»
- SOD () (CNP) (28)
(50-100 , 500 12 )
===== ,
– 50 1800
– - . .
.
– 2 . .
- – .
() - :
300 ,
200 ,
R- -
Na-R-ALA ( R- , R-ALA)
300 , ,
, 600 Na-RALA ( - ) R- – 250-300 . 50 .
40 – – .
- , , .. ( 600 ), -.
R- () Na-RALA , , , , .. , . - , , R, S, .
R- () Na-RALA , - . .
- , ( ).
- ( -L-). , . ( , – . , )
=====
,
(121 1 ) (36).
.
, ..
|
- |
|
:
»» 3 - 2005
- - , .
. , a- () . a- , - , .
. , , , . () - , () [7,12].
: 1) ( ); 2) . , , , , , , , . , . , , , -, . [2, 3, 8,14].
1,5 % , . , 2—3 %, — () . . . , - - , , , — . , . : ) , ; ) , , . , , .
(). . , , [11,13].
. , . , , , . - , , [11, 13].
, , , . . ( 2, 6, 12, , , , D, ), ( , , , ) , , . . , , , , , . , , , , , , (, .), .
, (), , .
" " , . ( ) ( ). ( ). ( ), , ( ). . , ( ). , . : 1) , ; 2) ; 3) [5, 9].
, . , [9, 10]. . (, , ), . : 1) ( , , , , .); 2) ; 3) ; 4) ; 5) , .
, , . . , , . , . , , — (-), -6 (-6) -8 (-8). , . , , -, -6 (Ito) . , — [5, 13, 14].
(, , , , , .). , , , , . — . .
: - (). (, ). . ( , , ) .
- — " ". , . , , . — " ", . , .
, . :
: 1) ; 2) ( ); 3) , ; 4) - (, , - ).
|
|
|
|
|
|
|
|
(, .) |
+ |
+ |
+! |
+! |
+ |
+ |
± |
|
+! |
+! |
+! |
+! |
+ |
+ |
+! |
|
+ |
+ |
+ |
+ |
+ |
+ |
+ |
( ) |
+ |
+ |
+ |
+! |
+ |
± |
± |
|
+ |
? |
? |
+! |
? |
? |
± |
( ) |
? |
? |
+! |
? |
? |
+! |
? |
- |
± |
± |
± |
± |
± |
+! |
± |
- ( ) |
+ |
+ |
+ |
+ |
+ |
+! |
± |
|
+! |
+! |
± |
+ |
+ |
+! |
± |
|
+ |
+ |
+ |
+ |
+! |
+! |
± |
. - ; - ;"+!" - ,"+" - , "±" - .
, . , : 1) ; 2) ; 3) - ; 4) [4, 15]. , :
, , , 3—6 . ( 6, 2, , 12, ) 10—14 [3].
: 1) ; 2) [9,11].
, . (. ).
: 1) ; 2) ; 3) ; 4) - ; 5) ; 6) , — .
- () (; ). , [1,14]. , . -, - — . 3 , . , , , .
. , — , , . . , , . [13]. . , , , , , , . , , , , , , . . ( , ), Q10, .
[1, 4]:
. . , , - 600 , 300 3 200 2 , . , , . [6]. , ( , ) .
() 600, — 1200 /. 2—6 . — ( 600 ), - . 20 , . , . , , ; , , .
, , () .
1. .., . // . 2000. 6. . 29-34.
2. .., ., .. . // . , , -. 2002. 5. . 40-44.
3. .., .. : // . 2003. . 11. 5. . 291-296.
4. Angulo P. Treatment of nonalcoholic fatty liver disease. Ann Hepatol 2002; V. 12-9.
5. Angulo P, Keach JC, Batts KP, Lindord KD. Independent predictors of Liver fibrosis in patients
with non-alcoholic steatohepatitis. Hepatology 1999;30:1356-62.
6. Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alhalipoic acid (thioctic acid), silymarin and selenium: tree case histories. Med Klin 1999; 15(Suppl. 3):84-89.
7. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pat//1998;15:246-58.
8. James O, Day CP. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999; 353:1634-36.
9. Kuntz E. Fatty liver - a morphological and clinical review. Med Welt 1999;50:406-13.
10. Lefkowitch JH. Hepatobiliary pathology. Curr
Opin Gastroenterol 2003;19:185-93.
11. Lumeng L, Crabb DW. Alcoholic liver disease. Curr Opin Gastroenterol 2000;16:208-18.
12. Moseley RH. Liver and biliary tract. Curr Opin Ga -stroenterol 2003;19:181-84.
13. Niemela O, Parkkila S, Yla-Herttuala S, et at. Sequential acetaldehyde production, lipid peroxi-dation and fibrogenesis in micropig model of alcohol-induced liver disease. Hepatology 1995; 22:1208-14.
14. Pessayre D, Mansouri AM, Fromenty B. Nonalcoholic steatosis and steatohepatitis. Mitochondria! dysfunction in steatohepatitis. Am 1 Physiol 2002;282:193-99.
15. PrichardP, WalfR, Chapman R. Drugs for the gut. WB Saunders Company Ltd 1998:443.
1 2005 .
|
-3 |
|
(, , ), , , -3...
\.
.
1-3 , - 3 - .
, EPA DHA , ( ) . , .
: EPA . , / - - ( 400 ME). , ( 2,5 - 3 ) EPA 1 - : , III.
: DHA ().
6 DHA 120 . , 1 2 .
10 -3 ( 3 ) - .
1998 , 3 , .
, , , . ( , - ), , - , , , Ritskes-Hoitinga.
, .
?
- . , .
-3, (400), ( 100 ) Q10 ( 30 ).
, , .
, ( 8 ) MRM.
. -.
Mercola. , ( ). .
, 8 , iherb .
Q10 , , . , . 48 , .
, - . - .
-3
1. .
- - , , . - (/Astaxanthin). - , .
, , 8- , 4,4 600 (230 154 ), 27%. , - .
- , 42% . , , , (Albert, 2015).
Krill Oil.
2 , 3-4 . California Gold Nutrition, 120 1 .
Natrol - 30 1 Healthy Origins, 60 500 .
"Kriloil Omega-3" " Kriella".
2.
, , , . , . .
Ascenta NutraSea, 1000 500 .
3. , -
, , : 70 DHA 140 DHA ..
, , .
, (, ). , - (), - .
, ( ) - . , , .
, , , : , , .
, , , : , (body) - .
-3 , . , - /, ( , ) (Foran, J Nutr 2005).
4. , -3. Nordic Naturals (195 /97 ).
, - , . .
5. .
-3 - - (ALA)
, , . (55 %), (32 %), (32 %), (20 %), (5 %) . .
, - 8% , 0-4% . 21% ALA EPA 9% - DHA.
, -, . , ( , ).
ALA DHA - , DHA , . , ALA , .
- , .
, - , - , . .
- , , , , , / GLA ( ), .
, GLA 480 . , 1. , .
, () . .
, , ( ).
200-240 ( 2000-3000 ) 3 , 100-120 , , , - 3 200-240 .
- Borago, 1 240 .
: - .
2010 Dyerberg, PLEFA , 37% , (EE), - 24% , .
(TG) (rTG), . rTG -3 EPA DHA . -
-3, 80% ( 30%).
, rTG- -3 5 -3 , 3,5 , . , rTG ( ).
, , , – . .
, , , -3 "Lovaza" Omacor. 2 (930 , 750 ) 48 20-30%, «» – 30-40%.
, "Epanova" AstraZeneca 2 (1 = 500-600 , 150-250 ) 30%. .
Epanova , Lovaza . , Omacor Lovaza . () . , - , .
- (TG) (rTG) Carlson Labs.
:
1) Carlson Labs 3,6,7,9: 1400. 180 . : 1 , (TG), 125 /110 . : , , .
2) Natrol - (TG): 180/ 120. : , , , . 400 , 150 .
3) Solgar: , 160 / 100 (, , ). 120 , 660 .
4) Coromega - 625 / 425 . 60 , 1700 .
(rTG), "--" ( , ). , 300% . , . , . - "" )
5) Madre Labs - 700 1 ! 450 30 (rTG, , )
6) Madre Labs: 480, 320 - 480 / 320 (TG, , ) 500 , 30 .
7) 180/ 120 Madre Labs (TG, , , / ). 400 , 100 .
8) Zenwise Health - 1800 , 120 , 688 /263 (rTG, ). - - . , .
9) Sports Research - rTG . 2300 , 180 . 687 /250 .
10) Minami Nutrition, MorEPA - 30 1300, 60 2400. rTG 756 /228 (, ).
10) Nordic Naturals "DHA Xtra" - 1550 , 60 : 205 480 !
, rTG ( ), , rTG.
11) 5:1 \ Carlson Labs - 500 - - , , . ( ). 120 , 1530.
-3+q10, 180 120 . : Q10 30 , 6, 27,5 . 30 500 . , 2 , - .
? .
.
85- ( ) . 85- . 85 .
, (150 ). , , .
, , , , - .
, 90 1200 D 4 , . (Tuna Albacore,Tuna luefin) (Lake Trout), .
EPA DHA 15,7 0,7 , 11,0 9,1 , 6,2 9,1 .
, , -3 (Foran, J Nutr 2005).
-3. , , (Aursand, J Sci Agr 2006).
(3-6-9) 3 , 3. - , , , . , 3-6, 3-6-9.
3ooo .
1000 .
1200 4000 .
(3-5 ) , , , , . 1 3 .
2 , .
3 6. , 5 1.
, , 1- 1.5 .
DHA :
· (2 );
· (250 / );
· (250 / ).
:
· (2 );
· (250 / ).
, - , , , .
, - , . , , .
, , - . , , - .
, , - . , , - (3-5 ).
, - " " Carlson Labs. 120 500 . )
- , - " " (350 1 ). , :) !
- , " ", - 700 . -. - ... )
, , - Coromega . - ! , , :) ...
3, .
, . , 10 ) - !
|
|
|
1
-https://cyberleninka.ru/article/n/ekstrakt-vinogra...azatelstv-sovremennosti/viewer
- : 100 200 2 2 ,
-
2,-
-https://medi.ru/info/3593/
|
. |
|
:
, !
, - !!!
- !!!!
******
— ., .
, , , 2,0
. , 1 . 5,0 , .
500 , 4 .
.
:
« , «» — , , , , , , , ».
, .
. , . . , (, , ). http://www.aromalogy.info/news/a-419.html — © Aromalogy
.
|
! { _ : .. |
! { _ : .. .( TalLisman)}
( !) 50 1.2% - , , . -, - . , .
. .
- () - ( ), -.
"- , . - .
-, - : , . , . , - . - .
, - . ."
" (ALA) ."
" , , . . ." ()
:
:
- , ( ), , () , . , ( ) ( ).
- , . , , .
- Q 10
-
- , ,
- , , ,
-
- -, ,
-
- , .
- ( ) ,- . .
, (50, ()!!!- !!!)- 200.
, - ( ). - . , ( , ) , 10 . , ( ) ( ) . , , , .
: |
: | [2] 1 |